I am a PennyStocking Silver member!! O.K. so more about myself. I have been studying about 5 years, I have been doing some trading on my own. I also, have been discovering technics on my own. I have won more on bluechip stocks than pennystocks. Overall I am probably down $350. I have made other comments about my past losers and winners. To get fully upto speed-I have won on $AMD in at $11.40 out at $12.98 with 52 shares a gain of $62.45. I loss at APTO in at $1.32 and out at $1.13 on 496 shares a loss of $94.24 $MSFT is such a small winner at $1.06 $RIGL was a big losser for me I had this one long term, in at $3.54 and sold at $2.74 with a loss of $50.37 4.4.17 I was not comfortable going to big today, so I already had one on my watchlist... ZENO in at $1.47 out at $1.67 with 482 shares with a gain of $82.48 I am currently holding SHOP, SNAP and BSGM
[TimAlerts] hopefuly $RIGL tests yesterdays's highs for a short
[TimAlerts] gm michael what do you think of $RIGL looking like a ascending triangle
[TimChallenge] hey turbobob any thoughts on $RIGL ? got in on panic dip bounce at 2.36 this morning now holding o/n, shot up to 2.90s before heavy selling back down to 2.70s at close...close reading shows the "bad news" may not have been so bad...somewhat bullish back to the 3s IMO, shareholders believe in the drug and they're taking it to FDA
[TimAlerts] $RIGL closing in on $3 makes my option play in the money 4 months early if it holds over the weekend
[TimAlerts] $RIGL has been on a tear
[TimChallenge] $RIGL :) got in at 2.36 this morning for small 250 shares
[TimAlerts] $RIGL wall of sellers here
[TimAlerts] $RIGL nhod
[TimAlerts] $RIGL might try to fill that gap.
[TimAlerts] $RIGL couple little spikes
[TimAlerts] $RIGL the reason is the delta if this stock ever hits $3 before end of the year I could make 70% calls were under valued
[TimAlerts] $RIGL piper reiterates overweigh PT $11 went long 4 calls at $0.25 march exp $5 strike
[TimAlerts] $RIGL shares dropped 32 percent to $2.19 after the company reported results from the second FIT Phase 3 study for fostamatinib. The company disclosed that the study did not meet primary endpoint.
[TimAlerts] starter short $RIGL 2.51
[TimAlerts] called out dead cat bounce on $RIGL @ 2.05. Just hit hod @2.52
[TimAlerts] $RIGL nhod
Join now or log in to leave a comment